CymaBay scraps key NASH, PSC programs after lead drug triggers safety alarms — share price implodes
When CymaBay Therapeutics recently acknowledged defeat in a 12-week readout of its Phase II trial of seladelpar, the biotech grasped at “significant improvements in biochemical …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.